Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	384 people 2 RCTs in this analysis	At least 1 adverse effect with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	RR 0.98 95% CI 0.92 to 1.05		Not significant
Systematic review	301 people Data from 1 RCT	QTc prolongation with risperidone (6 mg/day) with aripiprazole (20–30 mg/day) Absolute results not reported	RR 0.07 95% CI 0.00 to 1.35		Not significant
Systematic review	383 people 2 RCTs in this analysis	QTc abnormalities: mean difference in change from baseline (ms) with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	Mean difference –7.19 ms 95% CI –12.19 ms to –2.19 ms	Effect size not calculated	aripiprazole
Systematic review	83 people Data from 1 RCT	Mean difference in change from baseline in cholesterol (mg/dL) with risperidone (6 mg/day) with aripiprazole (15 mg/day) Absolute results not reported	Mean difference –22.3 mg/dL 95% CI –39.69 mg/dL to –4.91 mg/dL	Effect size not calculated	aripiprazole
Systematic review	384 people 2 RCTs in this analysis	Akathisia with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	RR 0.64 95% CI 0.09 to 4.72		Not significant
Systematic review	301 people Data from 1 RCT	Dystonia with risperidone (6 mg/day) with aripiprazole (20–30 mg/day) Absolute results not reported	RR 0.14 95% CI 0.05 to 0.41	Large effect size	aripiprazole
Systematic review	384 people 2 RCTs in this analysis	Extrapyramidal symptoms with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	RR 0.84 95% CI 0.49 to 1.47		Not significant
Systematic review	301 people Data from 1 RCT	Parkinsonism with risperidone (6 mg/day) with aripiprazole (20–30 mg/day) Absolute results not reported	RR 7.39 95% CI 0.43 to 128.08		Not significant
Systematic review	301 people Data from 1 RCT	Tremor with risperidone (6 mg/day) with aripiprazole (20–30 mg/day) Absolute results not reported	RR 4.66 95% CI 1.11 to 19.59	Moderate effect size	risperidone
Systematic review	83 people Data from 1 RCT	Use of antiparkinsonian medication with risperidone (6 mg/day) with aripiprazole (15 mg/day) Absolute results not reported	RR 0.59 95% CI 0.32 to 1.12		Not significant
Systematic review	301 people Data from 1 RCT	Abnormally high prolactin value with risperidone (6 mg/day) with aripiprazole (20–30 mg/day) Absolute results not reported	RR 0.04 95% CI 0.02 to 0.08	Large effect size	aripiprazole
Systematic review	91 people Data from 1 RCT	Dysmenorrhoea with risperidone (6 mg/day) with aripiprazole (20–30 mg/day) Absolute results not reported	RR 3.17 95% CI 0.17 to 59.43		Not significant
Systematic review	383 people 2 RCTs in this analysis	Mean difference in change from baseline in prolactin (ng/mL) with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	Mean difference –54.71 ng/mL 95% CI –60.06 ng/mL to –49.36 ng/mL	Effect size not calculated	aripiprazole
Systematic review	384 people 2 RCTs in this analysis	Weight gain of 7% or more of total body weight with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	RR 0.77 95% CI 0.33 to 1.82		Not significant
Systematic review	383 people 2 RCTs in this analysis	Mean change from baseline in weight (kg) with risperidone (6 mg/day) with aripiprazole (15–30 mg/day) Absolute results not reported	Mean difference –0.54 kg 95% CI –1.24 kg to +0.15 kg		Not significant